Chemical Control of Misfolded Protein Fate
Chemical Control of Misfolded Protein Fate
批准号:
10473133
负责人:
Fleur Marcia Ferguson
金额:
$142.2万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-28 至 2025-08-31
关键词:
AddressAlzheimer&aposs DiseaseAmericanAmyloidosisAreaCellsCellular StressChemicalsDegenerative DisorderDementiaDevelopmentDiseaseDisease ProgressionEtiologyFrontotemporal DementiaFutureGoalsHuntington DiseaseMediator of activation proteinMolecularNeurodegenerative DisordersNeuronsParkinson DiseasePathologicPathologyPhenotypeResearchRisk FactorsScientistTechnologyTherapeuticcancer therapyimprovedin vivoinnovationinsightmisfolded proteinnovel therapeutic interventionprotein degradationproteostasissmall moleculetau Proteinstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
7. Project Summary
The accumulation of misfolded proteins concurrent with disease progression is a hallmark of
degenerative disorders known collectively as proteinopathies. These include dementias such as
Alzheimer’s, Parkinson’s and Huntington’s Disease among many others, as well as systemic
amyloidosis disorders. However, if and how aggregated species contribute to disease etiology
and progression remains poorly understood. Over the past 100 years, there has been significant
advancement in understanding the pathological signatures and risk factors of proteinopathies but
the molecular mechanisms of disease have remained elusive. In this application, I propose the
development of new chemical tools for selectively manipulating aggregate proteostasis in cells
and in vivo using a targeted protein degradation approach. To demonstrate feasibility, this
approach was previously applied to investigate misfolded tau, leading to new insights into tau as
a mediator of cell stress vulnerability in frontotemporal dementia neurons. Several strategies are
presented to improve the throughput, scope, and utility of this approach across proteinopathies,
as well as future applications.
The major innovation of the proposed research is to take technologies and concepts learned from
the field of targeted protein degradation (TPD) for cancer therapy, which has been an
exceptionally active and successful area of research over the past 5 years, and apply them to
central challenges in neurodegenerative diseases, where TPD has yet to be applied broadly. I
believe this approach has high potential to yield significant advancement in both our
understanding of the molecular mechanisms underlying neurodegenerative diseases and in
identifying new therapeutic strategies to treat them.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文